Non-small cell lung cancer (NSCLC) Clinical Trials

Q: Are non-small cell lung cancer (nsclc) clinical trials free to join?

Yes. Participating in a non-small cell lung cancer (nsclc) clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.

Q: Who can join a non-small cell lung cancer (nsclc) clinical trial?

Each non-small cell lung cancer (nsclc) study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.

Q: How do I find a non-small cell lung cancer (nsclc) trial near me?

Use the location controls above. We'll show recruiting non-small cell lung cancer (nsclc) trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.

Q: How many non-small cell lung cancer (nsclc) trials are recruiting right now?

We're currently tracking roughly 329 recruiting non-small cell lung cancer (nsclc) trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.

Recruiting non-small cell lung cancer (nsclc) studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.

Clinical trials study new ways to prevent, detect, or treat non-small cell lung cancer (nsclc). Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting non-small cell lung cancer (nsclc) studies with sites across the US; use the location tools to find ones near you.

What to expect

Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.

Recruiting non-small cell lung cancer (nsclc) trials

Within

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

for Lung Non-Small Cell Carcinoma

14 sites incl. Newark

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07388524·Phase 3

Apply to this trial

ctDNA-Guided Intraventricular Therapy for CNS Malignancies

for Leptomeningeal Disease

Sponsor: Alireza Mansouri

Sex: All·Age: 18 - 120

Code: NCT07689721

A Multicenter Randomized Open-Label Trial Evaluating MRD-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

for NSCLC (Advanced Non-small Cell Lung Cancer)

Sponsor: Natera, Inc.

Sex: All·Age: 18+

Code: NCT07689812

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

1 site in Chicago

Sponsor: University of Chicago

Sex: All·Age: 18+

Code: NCT07603856·Phase 2

Apply to this trial

3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial

for Non Small Cell Lung Cancer

Sponsor: St. Joseph's Healthcare Hamilton

Sex: All·Age: 18+

Code: NCT06638125·Phase 1, Phase 2

Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

for Non Small Cell Lung Cancer

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Sex: All·Age: 18+

Code: NCT07234877·Phase 2

Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07579221·Phase 1, Phase 2

Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

1 site in Charleston

Sponsor: Medical University of South Carolina

Sex: All·Age: 18 - 80

Code: NCT07720167·Phase 2

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

for Anatomic Stage IV Breast Cancer AJCC v8

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06982222·Phase 1

The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

for Non-small Cell Lung Cancer

1 site in The Bronx

Sponsor: Montefiore Medical Center

Sex: All·Age: 18+

Code: NCT07146230·Phase 2

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

for Non-Small Cell Lung Cancer

34 sites incl. Beverly Hills

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07680790·Phase 3

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

for Lung Non-Small Cell Carcinoma

1 site in Columbus

Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All·Age: All ages

Code: NCT06816979

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

for Non Small Cell Lung Cancer

Sponsor: Fundación GECP

Sex: All·Age: 18+

Code: NCT07247786·Phase 2

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

for Metastatic Lung Non-Small Cell Carcinoma

1 site in Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+

Code: NCT07619599·Phase 1

Vapor Ablation for Localized Cancer Lesions

for Non Small Cell Lung Cancer

Sponsor: Uptake Medical Technology, Inc.

Sex: All·Age: 18+

Code: NCT03514329

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

for Advanced Lung Non-Small Cell Carcinoma

1 site in Seattle

Sponsor: University of Washington

Sex: All·Age: 18+

Code: NCT07322341·Phase 2

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT07541170·Phase 3

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

for Clinical Stage III Cutaneous Melanoma AJCC v8

Sponsor: Fred Hutchinson Cancer Center

Sex: All·Age: 18+

Code: NCT07576725·Phase 2

A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.

for Non-Small Cell Lung Cancer

Sponsor: First Affiliated Hospital of Guangxi Medical University

Sex: All·Age: 18+

Code: NCT07686185

In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing

for Carcinoma, Non-Small-Cell Lung

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Sex: All·Age: 18+

Code: NCT07697716

SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer

for NSCLC

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07697586·Phase 2

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

for Lung Non-Small Cell Carcinoma

1 site in Buffalo

Sponsor: Roswell Park Cancer Institute

Sex: All·Age: 18+

Code: NCT06943664·Phase 2

Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC

for Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Sun Yat-sen University

Sex: All·Age: 18+

Code: NCT07674524

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

for NSCLC

Sponsor: Swiss Cancer Institute

Sex: All·Age: 18+

Code: NCT07158489·Phase 2

Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study

for Stage II Lung Cancer

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT07412041

Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC

for Non Small Cell Lung Cancer

Sponsor: Peking University Cancer Hospital & Institute

Sex: All·Age: 18 - 75

Code: NCT07567326·Phase 2

TCR1188-ABC Cells in KRAS-mutated Cancers

for Cholangiocarcinoma

1 site in Philadelphia

Sponsor: University of Pennsylvania

Sex: All·Age: 18+

Code: NCT07594067·Phase 1

Apply to this trial

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

for Non-Small Cell Lung Cancer

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07622186·Phase 2

Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

for Non-small Cell Lung Cancer (NSCLC)

Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

Sex: All·Age: 18+

Code: NCT07624214·Phase 1

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

for Advanced Solid Tumor

4 sites incl. Durham

Sponsor: Clasp Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07650357·Phase 1

Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC

for NSCLC

Sponsor: Zhou Chengzhi

Sex: All·Age: 18+

Code: NCT07685197·Phase 2

Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC

for Non-Small Cell Lung Cancer

Sponsor: Shanghai Chest Hospital

Sex: All·Age: 18 - 80

Code: NCT07698990

HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion

for Non-Small Cell Lung Cancer

Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Sex: All·Age: 18+

Code: NCT07699757·Phase 1

Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

for Melanoma (Skin Cancer)

Sponsor: Institute of Cancer Research, United Kingdom

Sex: All·Age: 18+

Code: NCT07718243·Phase 1, Phase 2

A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)

for Carcinoma, Non-Small-Cell Lung

Sponsor: Janssen-Cilag Farmaceutica Ltda.

Sex: All·Age: 18+

Code: NCT07680907

The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With HER2 Over Expression

for NSCLC

Sponsor: Hunan Province Tumor Hospital

Sex: All·Age: 18+

Code: NCT07662473·Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer (NSCLC)

1 site in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 120

Code: NCT06694454·Phase 1, Phase 2

Apply to this trial

A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Weight Loss

for Non-small Cell Lung Cancer (NSCLC)

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07663630·Phase 1

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

for Carcinoma, Non-Small-Cell Lung

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07586202·Phase 2

Apply to this trial

Evaluation of XYA02 in Patients With Advanced Solid Tumors

for MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors

Sponsor: XYone Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT07670312·Phase 1, Phase 2

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

for Lung Non-Small Cell Carcinoma

33 sites incl. Jonesboro

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT07293247·Phase 2

Apply to this trial

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

1 site in Fairfax

Sponsor: Avistone Biotechnology Co., Ltd.

Sex: All·Age: 18+

Code: NCT07538804·Phase 1, Phase 2

Apply to this trial

Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

for Non-Small Cell Lung Cancer

Sponsor: Centre Georges Francois Leclerc

Sex: All·Age: 18+

Code: NCT05937906·Phase 1, Phase 2

Apply to this trial

Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer

for NSCLC

1 site in Dallas

Sponsor: University of Texas Southwestern Medical Center

Sex: All·Age: 22+

Code: NCT06552000

DK222 Study at Hopkins

for Non-Small Cell Lung Cancer

1 site in Baltimore

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: All·Age: 18+

Code: NCT07140315·Phase 1

Apply to this trial

Effects of a Visual Interactive LINE Chatbot on Self-Management of EGFR-TKI Related Side Effects in Patients With Lung Cancer

for Non-Small Cell Lung Cancer

Sponsor: National Taiwan University Hospital

Sex: All·Age: 18+

Code: NCT07310589

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

for Non-small Cell Lung Cancer

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07382726·Phase 1

Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities

for Non Small Cell Lung Cancer

Sponsor: Sun Yat-sen University

Sex: All·Age: 18 - 75

Code: NCT07630077·Phase 2

Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)

for Lung Cancer

Sponsor: Ain Shams University

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT06502249

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

1 site in New York

Sponsor: Beijing Pearl Biotechnology Limited Liability Company

Sex: All·Age: 18+

Code: NCT07285148·Phase 1, Phase 2

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

for NSCLC

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Sex: All·Age: 18 - 75

Code: NCT07358689·Phase 2

Pathophysiological Mechanisms Involved in the Pronostic and Evolution of Non-Small Cell Lung Cancer (NSCLC) at All Stages of the Disease

for Non Small Cell Lung Cancer

Sponsor: University Hospital, Bordeaux

Sex: All·Age: 18+

Code: NCT07470476

Boosting Osimertinib Blood Brain Barrier Penetration

for Non-Small Cell Lung Cancer

Sponsor: Maastricht University Medical Center

Sex: All·Age: 18+

Code: NCT07485452·Phase 2

Apply to this trial

A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma

for Pancreatic Adenocarcinoma

Sponsor: Chipscreen Biosciences, Ltd.

Sex: All·Age: 18+

Code: NCT07583771·Phase 1

A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

for Solid Tumor

Sponsor: Huahui Health

Sex: All·Age: 18 - 75

Code: NCT07623369·Phase 1

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

for Advanced Solid Tumor

1 site in Fairfax

Sponsor: Blueprint Medicines Corporation

Sex: All·Age: 18+

Code: NCT07629960·Phase 1, Phase 2

Apply to this trial

Intelligent Pulmonary Rehabilitation After Lung Cancer Surgery

for Non-Small Cell Lung Cancer

Sponsor: The First Affiliated Hospital of Guangzhou Medical University

Sex: All·Age: 18 - 75

Code: NCT07631520

Single-Center Intelligent Pulmonary Rehabilitation After Lung Cancer Surgery

for Non-Small Cell Lung Cancer

Sponsor: Jianxing He

Sex: All·Age: 18 - 75

Code: NCT07631533

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

for Non-small Cell Lung Cancer

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07642024·Phase 2, Phase 3

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

3 sites incl. Los Angeles

Sponsor: Verastem, Inc.

Sex: All·Age: 18+

Code: NCT07659782·Phase 2